DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES Russian patent published in 2018 - IPC A61K35/76 A61K39/235 A61K45/00 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the treatment of a tumor. Disclosed are a method for treating a tumor in a human patient comprising the systemic intravenous administration of a plurality of doses of the parenteral composition of a B subgroup oncolytic adenovirus capable of replicating (in particular, Ad11 / Ad3 chimeric adenovirus) within a single treatment cycle, wherein the total dose delivered at each administration is in the range of 1×10¹⁰ to 1×10¹⁴ virus particles per dose, and each dose of the virus is administered to ensure the delivery rate of the virus particles in the range of 2×10¹⁰ particles per minute to 6×10¹¹ particles per minute (variants), a method for treating a tumor by combined therapy, a method for treating ovarian cancer, uses of said B serogroup adenovirus for the treatment of a tumor in humans (variants), uses of a syringe containing a composition for injection or infusion with said B serogroup adenovirus.

EFFECT: technical result consists in determining the tolerable and safe dose of ColoAd1 for a human patient with a tumor and the conditions for its administration; the beneficial effect of the declared mode of administration on the pharmacokinetics of the virus and the elimination of non-cancerous viral scavengers; side effects of this dosing regime (fever, weakness) in some patients continued until the second week due to the ongoing replication of the virus in tumors.

28 cl, 25 dwg